PubMed Health⌕ Search

Biomedical subjects

B J Parikh

Publications and source records attributed to B J Parikh.

5 recordsLinked to original sources
PubMed1990

Recombinant alpha-interferon therapy in multiple myeloma.

Three patients with multiple myeloma were treated with recombinant alpha-interferon (r IFN-alpha 2b Intron AR) along with combination chemotherapy i.e. melphelan and prednisolone. In one case it was given as an initial therapy, while the other two patients had refractory and relapsing disease respectively. IFN-alpha 2b was given in the dose of 2 x 10(6) Mu/m2 by subcutaneous injection thrice in a week for six months in two patients and for three months in one patient. All three patients experienced improvement in bone pains; partial response with reduction in the paraprotein level was seen in one patient; while there was no radiological, biochemical or haematological improvement in two patients. Side effects noted were flu like syndrome in all three patients and urticaria in one patient. They were treated symptomatically and did not require cessation of interferon therapy.

Adult↗
PubMedDate not supplied

Clinical application of serum levels of sialic acid, fucose and seromucoid fraction as tumour markers in human leukemias.

To establish a blood-based biochemical profile for diagnosis and management of human leukemias, serum total sialic acid/total protein, lipid bound sialic acid, fucose/total protein and seromucoid fraction (quantitated as its hexoses and protein contents) levels were measured by highly specific spectrophotometric methods. Compared to the controls (n = 150), all the biomarkers were significantly elevated in anemia patients (pathological controls, n = 77) and untreated leukemia patients (n = 145). Furthermore, significantly raised levels of the markers were observed in untreated leukemia patients compared to anemia patients. Fucose/total protein was the most specific (71.0%) marker, while hexose levels were the most sensitive (93.0%) marker for leukemia. The levels of the biomarkers in patients with persistent leukemic activity/accelerated leukemic phase were significantly higher than those in patients in remission and were comparable with pretreatment levels. The study suggested that the markers evaluated are useful in diagnosis and treatment monitoring of leukemia patients.

Acute Disease↗